Predictors of Myasthenia Gravis Outcome Following Thoracoscopic Thymectomy: Comparative Study Between Thymomatous and Non-Thymomatous Patients

Predictors of Myasthenia Gravis Outcome Following Thoracoscopic Thymectomy: Multicenter Comparative Study Between Thymomatous and Non-Thymomatous Patients

This study aimed to assess and compare predictors of outcome in patients with thymomatous and non-thymomatous MG undergoing Thoracoscopic thymectomy.

Myasthenia Gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by fluctuating muscle weakness resulting from antibodies that target acetylcholine receptors or associated proteins at the neuromuscular junction.

Thoracoscopic thymectomy becomes more prominent than traditional transsternal thymectomy due to fewer perioperative complications with shorter hospital stays and more favorable long-term outcomes.

Prognostic outcomes following thoracoscopic thymectomy can vary significantly between non-thymomatous and thymomatous MG, necessitating a thorough investigation of these differences.

Inclusion Criteria:

• Both sexes.
• Confirmed diagnosis of Myasthenia Gravis (MG).
• Underwent Thoracoscopic thymectomy.
• Availability of complete preoperative and postoperative records, including imaging and histopathology.
• Minimum follow-up of 9 months post-surgery.

Exclusion Criteria:

• Patients who underwent thymectomy for indications other than MG.
• Incomplete medical records or loss to follow-up before outcome assessment.
• Patients with concomitant neuromuscular disorders other than MG